康希諾生物-B(06185.HK):重組新冠疫苗(5型腺病毒載體)獲匈牙利頒發GMP認證
格隆匯5月23日丨康希諾生物-B(06185.HK)公佈,2021年3月22日公吿披露,內容有關重組新型冠狀病毒疫苗(5型腺病毒載體)(“Ad5-nCoV”,商品名稱為克威莎TM)獲匈牙利國家藥品與營養研究所(OGYéI)授予緊急使用授權。
公司欣然宣佈,匈牙利國家藥品與營養研究所(OGYéI)認為公司符合歐盟生產質量管理規範(GMP)標準和指導原則,並於2021年5月21日向公司頒發Ad5-nCoV的生產質量管理規範(GMP)認證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.